The agreement will benefit clinical trials, delivering Suvoda’s cutting edge IRT/IWRS technology for subject randomization and trial supply management integrated with PCI’s comprehensive packaging and logistical services for clinical trial supplies.
As a result of this collaboration, our customers will have access to Suvoda’s proprietary IRT system with ‘Modularity’. Offering the speed of a configurable system with the flexibility of a custom-built solution, this results in rapid deployment and best-in-class functionality for clients looking to implement an IRT technology platform for their global studies.
We will also integrate the Suvoda IRT system into its own clinical supply network technologies, providing a seamless solution for stakeholders with real-time customized access for various facets of investigational studies, including trial data and visibility across the global supply chain.
Bob Misher, Senior Vice President for PCI Clinical Services, said: “The partnership between PCI and Suvoda underscores our commitment in delivering a world-class customer experience. In our evaluation we have found the Suvoda technology and customer commitment to be truly best-in-class.
“Our partnership with Suvoda will enable sponsors to leverage the combined power of our respective expertise in a seamless and efficient manner, working collaboratively to deliver an outstanding user experience and ultimately help enable more successful outcomes for their clinical studies through a comprehensive technology and supply solution.”
Suvoda’s IRT system with Modularity enables the services team to select modules from a central library, configure them for a specific study, and create new modules to meet unique, study-specific needs resulting in rapid innovation with outstanding quality and compliance. In addition to offering best-of-breed functionality and re-imagined reporting, the IRT system also integrates into our own supply network for packaging and labeling services, global storage and distribution, as well as returns management including reconciliation and certified destruction of supplies.
This technology partnership is the latest in a series of significant investments across PCI’s European and North American clinical supply sites, supporting considerable business growth in this segment. PCI opened a state-of-the-art purpose built North American storage and distribution facility for clinical materials in 2014 and has announced a recent expansion of its Cold Chain and Ultra Cold Chain on-site storage to include liquid nitrogen storage for Advanced Therapeutic Medicinal Products (ATMP) including the rapid growing market for cell and gene therapies.
In addition, our recently announced significant site expansions to its European center of excellence for clinical trial services in Bridgend, United Kingdom, as well as its manufacturing center of excellence in Tredegar, United Kingdom. The European Bridgend location features extensive temperature controlled storage, complementing the investments in Cold Chain and Ultra Cold Chain storage made at the North America facility.
Tredegar’s manufacturing site expansion includes investment in additional XcelodoseTM drug-in-capsule technologies for early phase Clinical study, including pioneering fully contained XcelodoseTM technology for potent compound development. These investments continue to demonstrate PCI’s ongoing commitment to providing their clients an integrated global solution for investigational studies.